<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiovascular</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиоваскулярная терапия и профилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Cardiovascular Therapy and Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1728-8800</issn><issn pub-type="epub">2619-0125</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1728-8800-2023-3783</article-id><article-id custom-type="edn" pub-id-type="custom">TAHKSZ</article-id><article-id custom-type="elpub" pub-id-type="custom">cardiovascular-3783</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>МЕТОДОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>METHODOLOGY</subject></subj-group></article-categories><title-group><article-title>Гиперурикемия и артериальная гипертония у лиц трудоспособного возраста: результаты популяционного исследования</article-title><trans-title-group xml:lang="en"><trans-title>Hyperuricemia and hypertension in working-age people: results of a population study</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2087-6483</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шальнова</surname><given-names>С. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Shalnova</surname><given-names>S. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор, руководитель отдела эпидемиологии хронических неинфекционных заболеваний.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">svetlanashalnova@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9332-0622</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Имаева</surname><given-names>А. Э.</given-names></name><name name-style="western" xml:lang="en"><surname>Imaeva</surname><given-names>A. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., в.н.с. отдела эпидемиологии хронических неинфекционных заболеваний.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">imayeva@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9844-3122</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Куценко</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kutsenko</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>с.н.с. лаборатории биостатистики отдела эпидемиологии хронических неинфекционных заболеваний; аспирант кафедры теории вероятностей механико-математического факультета.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">vlakutsenko@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8011-2798</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Баланова</surname><given-names>Ю. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Balanova</surname><given-names>Yu. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., в.н.с. отдела эпидемиологии хронических неинфекционных заболеваний.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">JBalanova@gnicpm.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9624-9374</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Капустина</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kapustina</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>с.н.с. отдела эпидемиологии хронических неинфекционных заболеваний.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">akapustina@gnicpm.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8984-9056</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шепель</surname><given-names>Р. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Shepel</surname><given-names>R. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., зам. директора по перспективному развитию медицинской деятельности, руководитель отдела научно-стратегического развития первичной медико-санитарной помощи, доцент кафедры общественного здоровья и организации здравоохранения, доцент кафедры терапии и профилактической медицины.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">rshepel@gnicpm.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4453-8430</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Драпкина</surname><given-names>О. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Drapkina</surname><given-names>O. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор, академик РАН, директор, зав. кафедрой терапии и профилактической медицины.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">Odrapkina@gnicpm.ru</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ "Национальный медицинский исследовательский центр терапии и профилактической медицины" Минздрава России</institution></aff><aff xml:lang="en"><institution>National Medical Research Center for Therapy and Preventive Medicine</institution></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБУ "Национальный медицинский исследовательский центр терапии и профилактической медицины" Минздрава России; ФГБОУ ВО "Московский государственный университет им. М.В. Ломоносова"</institution></aff><aff xml:lang="en"><institution>National Medical Research Center for Therapy and Preventive Medicine; Lomonosov Moscow State University</institution></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБУ "Национальный медицинский исследовательский центр терапии и профилактической медицины" Минздрава России; ФГБОУ ВО "Московский  государственный медико- стоматологический университет им. А.И. Евдокимова" Минздрава России</institution></aff><aff xml:lang="en"><institution>National Medical Research Center for Therapy and Preventive Medicine; A.I. Evdokimov Moscow State Medical University</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>28</day><month>01</month><year>2024</year></pub-date><volume>22</volume><issue>9S</issue><issue-title>Первичная медико-санитарная помощь</issue-title><fpage>3783</fpage><lpage>3783</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Шальнова С.А., Имаева А.Э., Куценко В.А., Баланова Ю.А., Капустина А.В., Шепель Р.Н., Драпкина О.М., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Шальнова С.А., Имаева А.Э., Куценко В.А., Баланова Ю.А., Капустина А.В., Шепель Р.Н., Драпкина О.М.</copyright-holder><copyright-holder xml:lang="en">Shalnova S.A., Imaeva A.E., Kutsenko V.A., Balanova Y.A., Kapustina A.V., Shepel R.N., Drapkina O.M.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://cardiovascular.elpub.ru/jour/article/view/3783">https://cardiovascular.elpub.ru/jour/article/view/3783</self-uri><abstract><sec><title>Цель</title><p>Цель. Изучить распространённость гиперурикемии (ГУ) и подагры в зависимости от артериальной гипертонии (АГ), а также оценить их ассоциации со смертностью российской популяции.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. В анализ были включены данные, полученные в двух одномоментных исследованиях — ЭССЕ-РФ и ЭССЕРФ2. Все участники исследования были опрошены по вопроснику, сформированному по модульному принципу. Мочевая кислота (МК) определялась в сыворотке крови уриказным методом. ГУ соответствовала уровню МК &gt;420 мкмоль/л у мужчин и &gt;360 мкмоль/л у женщин. В качестве бессимптомной ГУ в настоящем исследовании рассматривали ГУ без подагры. Ассоциации с конечными точками оценены с помощью моделей пропорциональных рисков Кокса с приведением соответствующих отношений рисков.</p></sec><sec><title>Результаты</title><p>Результаты. Распространённость ГУ в среднем составила 18,2%. Частота ГУ, как и ожидалось, преобладала среди мужской когорты — 22,6% vs 15,7%, соответственно. Распространенность бессимптомной ГУ была на 4,4% выше среди мужчин по сравнению с женщинами. Распространенность подагры увеличивалась с возрастом и в среднем составила 2,6% во всей популяции. Выявлено высокое содержание МК у мужчин в отсутствие АГ. Распространенность ГУ у женщин с АГ была в 3 раза выше, по сравнению с участницами без АГ. В мужской когорте в группе АГ без ГУ смертность от всех причин и от сердечно-сосудистых заболеваний (ССЗ) достоверно увеличивается, а группе с АГ и ГУ — только смертность от всех причин. У женщин риск смерти от ССЗ увеличивался в случае наличия АГ — отношение рисков 3,98 (95% доверительный интервал 1,86-8,52). При этом у женщин с АГ и ГУ риск смерти от всех причин увеличивался на 66%, риск смерти от ССЗ в 6,7 раз.</p></sec><sec><title>Заключение</title><p>Заключение. У каждого пятого участника исследования была выявлена ГУ. Частота ГУ у мужчин с АГ была примерно в 1,5 раза больше, чем без АГ, у женщин с АГ ГУ выявлялась в 3 раза чаще, чем без АГ, что может свидетельствовать о более выраженной взаимосвязи АГ и ГУ у женщин. Показано, что ГУ может ухудшать прогноз АГ. Таким образом, контроль и своевременная коррекция уровня МК у лиц, страдающих АГ, становятся необходимыми мерами для улучшения прогноза в отношении смерти от всех причин и ССЗ.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To study the prevalence of hyperuricemia (HU) and gout depending on hypertension (HTN), as well as to evaluate their associations with mortality in the Russian population.</p></sec><sec><title>Material and methods</title><p>Material and methods. The analysis included data obtained in two cross-sectional studies — ESSE-RF and ESSE-RF2. All study participants were surveyed using a modular designed questionnaire. Serum uric acid (UA) was determined using the uricase method. HU corresponded to a UA &gt;420 µmol/l in men and &gt;360 µmol/l in women. HU without gout was considered asymptomatic HU in the present study. Associations with endpoints were assessed using Cox proportional hazards models with associated hazard ratios.</p></sec><sec><title>Results</title><p>Results. The average prevalence of HU was 18,2%. HU, as expected, predominates among the male cohort — 22,6% vs 15,7%, respectively. The prevalence of asymptomatic HU was 4,4% higher among men compared to women. The prevalence of gout increased with age and averaged 2,6% in the entire population. A high content of UA was revealed in men in the absence of hypertension. The prevalence of HU in women with HTN was 3 times higher than in participants without hypertension. In the male cohort, in the group of hypertension without HU, all-cause and cardiovascular mortality significantly increases, and in the group with hypertension and HU, only all-cause mortality increases. In women, the cardiovascular death risk increased in HTN — hazard ratio 3,98 (95% confidence interval 1,86-8,52). At the same time, in women with HTN and HU, all-cause and cardiovascular death risk increased by 66% and 6,7 times, respectively.</p></sec><sec><title>Conclusion</title><p>Conclusion. Every fifth study participant was diagnosed with HU. The prevalence of HU in hypertensive men was approximately 1,5 times higher than without hypertension. In women with HTN, HU was detected three times more often than without HTN, which may indicate a more pronounced relationship between HTN and HU in women. HU can worsen the HTN prognosis. Thus, monitoring and timely correction of UA levels in hypertensive patients become necessary to improve the prognosis.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>гиперурикемия</kwd><kwd>подагра</kwd><kwd>артериальная гипертония</kwd><kwd>общая смертность</kwd><kwd>сердечно-сосудистая смертность</kwd></kwd-group><kwd-group xml:lang="en"><kwd>hyperuricemia</kwd><kwd>gout</kwd><kwd>hypertension</kwd><kwd>all-cause mortality</kwd><kwd>cardiovascular mortality</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Bursill D, Taylor WJ, Terkeltaub R, et al. Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. Ann. Rheum. Dis. 2019;78(11):1592-600. doi:10.1136/annrheumdis-2019-215933.</mixed-citation><mixed-citation xml:lang="en">Bursill D, Taylor WJ, Terkeltaub R, et al. Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. Ann. Rheum. Dis. 2019;78(11):1592-600. doi:10.1136/annrheumdis-2019-215933.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. New England journal of medicine. 2008;359(17):1811-21. doi:10.1056/NEJMra0800885.</mixed-citation><mixed-citation xml:lang="en">Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. New England journal of medicine. 2008;359(17):1811-21. doi:10.1056/NEJMra0800885.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. Jama. 2008;300(8):924-32. doi:10.1001/jama.300.8.924.</mixed-citation><mixed-citation xml:lang="en">Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. Jama. 2008;300(8):924-32. doi:10.1001/jama.300.8.924.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Soletsky B, Feig DI. Uric acid reduction rectifies prehypertension in obese adolescents. Hypertension. 2012;60(5):1148-56. doi:10.1161/HYPERTENSIONAHA.112.196980.</mixed-citation><mixed-citation xml:lang="en">Soletsky B, Feig DI. Uric acid reduction rectifies prehypertension in obese adolescents. Hypertension. 2012;60(5):1148-56. doi:10.1161/HYPERTENSIONAHA.112.196980.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Taniguchi Y, Hayashi T, Tsumura, K, et al. Serum uric acid and the risk for hypertension and Type 2 diabetes in Japanese men: The Osaka Health Survey. Journal of hypertension. 2001;19(7):120915. doi:10.1097/00004872-200107000-00005.</mixed-citation><mixed-citation xml:lang="en">Taniguchi Y, Hayashi T, Tsumura, K, et al. Serum uric acid and the risk for hypertension and Type 2 diabetes in Japanese men: The Osaka Health Survey. Journal of hypertension. 2001;19(7):120915. doi:10.1097/00004872-200107000-00005.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Masuo K, Kawaguchi H, Mikami H, et al. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension. 2003;42(4):474-80. doi:10.1161/01.HYP.0000091371.53502.D3.</mixed-citation><mixed-citation xml:lang="en">Masuo K, Kawaguchi H, Mikami H, et al. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension. 2003;42(4):474-80. doi:10.1161/01.HYP.0000091371.53502.D3.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">McMullan CJ, Borgi L, Fisher N, et al. Effect of uric acid lowering on renin-angiotensin-system activation and ambulatory BP: a randomized controlled trial. Clinical journal of the American Society of Nephrology: CJASN. 2017;12(5):807. doi:10.2215/CJN.10771016.</mixed-citation><mixed-citation xml:lang="en">McMullan CJ, Borgi L, Fisher N, et al. Effect of uric acid lowering on renin-angiotensin-system activation and ambulatory BP: a randomized controlled trial. Clinical journal of the American Society of Nephrology: CJASN. 2017;12(5):807. doi:10.2215/CJN.10771016.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Piani F, Cicero AFG, Borghi C. Uric acid and hypertension: prognostic role and guide for treatment. Journal of Clinical Medicine. 2021;10(3):448. doi:10.3390/jcm10030448.</mixed-citation><mixed-citation xml:lang="en">Piani F, Cicero AFG, Borghi C. Uric acid and hypertension: prognostic role and guide for treatment. Journal of Clinical Medicine. 2021;10(3):448. doi:10.3390/jcm10030448.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Brook RA, Forsythe A, Smeeding JE, Lawrence Edwards N. Chronic gout: epidemiology, disease progression, treatment and disease burden. Current medical research and opinion. 2010;26(12): 2813-21. doi:10.1185/03007995.2010.533647.</mixed-citation><mixed-citation xml:lang="en">Brook RA, Forsythe A, Smeeding JE, Lawrence Edwards N. Chronic gout: epidemiology, disease progression, treatment and disease burden. Current medical research and opinion. 2010;26(12): 2813-21. doi:10.1185/03007995.2010.533647.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Dalbeth N, Robinson PC. Patients with gout: an under-recognised group at high risk of COVID-19. The Lancet Rheumatology. 2021;3(5):e317-e318. doi:10.1016/S2665-9913(21)00073-4.</mixed-citation><mixed-citation xml:lang="en">Dalbeth N, Robinson PC. Patients with gout: an under-recognised group at high risk of COVID-19. The Lancet Rheumatology. 2021;3(5):e317-e318. doi:10.1016/S2665-9913(21)00073-4.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Nossent J, Raymond W, Divitini M, Knuiman M. Asymptomatic hyperuricemia is not an independent risk factor for cardiovascular events or overall mortality in the general population of the Busselton Health Study. BMC Cardiovasc Disord. 2016;16(1): 256. doi:10.1186/s12872-016-0421-1.</mixed-citation><mixed-citation xml:lang="en">Nossent J, Raymond W, Divitini M, Knuiman M. Asymptomatic hyperuricemia is not an independent risk factor for cardiovascular events or overall mortality in the general population of the Busselton Health Study. BMC Cardiovasc Disord. 2016;16(1): 256. doi:10.1186/s12872-016-0421-1.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Petreski T, Ekart R, Hojs R, et al. Asymptomatic hyperuricemia and cardiovascular mortality in patients with chronic kidney disease who progress to hemodialysis. Int Urol Nephrol. 2019; 51:1013-8. doi:10.1007/s11255-019-02154-w.</mixed-citation><mixed-citation xml:lang="en">Petreski T, Ekart R, Hojs R, et al. Asymptomatic hyperuricemia and cardiovascular mortality in patients with chronic kidney disease who progress to hemodialysis. Int Urol Nephrol. 2019; 51:1013-8. doi:10.1007/s11255-019-02154-w.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Chen C, Dong J, Lv Q, et al. Effect of Asymptomatic Hyperuricemia on Mortality of Elderly Patients After Elective Percutaneous Coronary Intervention. Front Cardiovasc Med. 2022;9:800414. doi:10.3389/fcvm.2022.800414.</mixed-citation><mixed-citation xml:lang="en">Chen C, Dong J, Lv Q, et al. Effect of Asymptomatic Hyperuricemia on Mortality of Elderly Patients After Elective Percutaneous Coronary Intervention. Front Cardiovasc Med. 2022;9:800414. doi:10.3389/fcvm.2022.800414.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Батюшин М. М. Распространённость бессимптомной гиперурикемии у больных с хронической болезнью почек и её влияние на течение и прогноз (опыт одного центра). Южно-Российский журнал терапевтической практики. 2022;3(1):7482. doi:10.21886/2712-8156-2022-3-1-74-82.</mixed-citation><mixed-citation xml:lang="en">Batiushin MM. The prevalence of asymptomatic hyperuricemia in patients with chronic kidney disease and its effect on the course and prognosis (experience of one center). South Russian Journal of Therapeutic Practice. 2022;3(1):74-82. (In Russ.) doi:10.21886/2712-8156-2022-3-1-74-82.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Научно-организационный комитет проекта ЭССЕ-РФ. Эпидемиология сердечно-сосудистых заболеваний в различных регионах России (ЭССЕ-РФ). Обоснование и дизайн исследования. Профилактическая медицина. 2013;16(6):25-34.</mixed-citation><mixed-citation xml:lang="en">Scientific and Organizational Committee of the project ÉSSERF. Epidemiology of cardiovascular diseases in different regions of Russia (ESSE-RF). The rationale for and design of the study. Profilakticheskaya Meditsina. 2013;16(6):25-34. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Баланова Ю. А., Имаева А. Э., Концевая А. В. Эпидемиологический мониторинг факторов риска хронических неинфекционных заболеваний в практическом здравоохранении на региональном уровне. Методические рекомендации под редакцией Бойцова С. А. М.; М.: Издательство Медиа Сфера, 2016. 111 с. EDN WLACDB.</mixed-citation><mixed-citation xml:lang="en">Balanova YA, Imaeva AE, Kontsevaya AV. Epidemiological monitoring of risk factors for chronic noncommunicable diseases in health care practice at the regional level. Methodological recommendations edited by S. A. Boytsov. М.: Media Sphere Publishing House, 2016. 111 p. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Wei PIAO, Bo YC, Zhao LY, Yu DM. Status of Serum Uric Acid and Hyperuricemia among Adults in China: China Nutrition and Health Surveillance (2015). Biomedical and Environmental Sciences. 2022;35(10):911-20. doi:10.3967/bes2022.118.</mixed-citation><mixed-citation xml:lang="en">Wei PIAO, Bo YC, Zhao LY, Yu DM. Status of Serum Uric Acid and Hyperuricemia among Adults in China: China Nutrition and Health Surveillance (2015). Biomedical and Environmental Sciences. 2022;35(10):911-20. doi:10.3967/bes2022.118.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Chen Xu M, Yokose C, Rai SK, et al. Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the National Health and Nutrition Examination Survey, 20072016. Arthritis &amp; rheumatology. 2019;71(6):991-9. doi:10.1002/art.40807.</mixed-citation><mixed-citation xml:lang="en">Chen Xu M, Yokose C, Rai SK, et al. Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the National Health and Nutrition Examination Survey, 20072016. Arthritis &amp; rheumatology. 2019;71(6):991-9. doi:10.1002/art.40807.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Wingrove CS, Walton C, Stevenson JC. The effect of menopause on serum uric acid levels in non-obese healthy women. Metabolism. 1998;47(4):435-8. doi:10.1016/S0026-0495(98)90056-7.</mixed-citation><mixed-citation xml:lang="en">Wingrove CS, Walton C, Stevenson JC. The effect of menopause on serum uric acid levels in non-obese healthy women. Metabolism. 1998;47(4):435-8. doi:10.1016/S0026-0495(98)90056-7.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Halperin Kuhns VL, Woodward OM. Sex differences in urate handling. International journal of molecular sciences. 2020; 21(12):4269. doi:10.3390/ijms21124269.</mixed-citation><mixed-citation xml:lang="en">Halperin Kuhns VL, Woodward OM. Sex differences in urate handling. International journal of molecular sciences. 2020; 21(12):4269. doi:10.3390/ijms21124269.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Stöckl D, Döring A, Thorand B, et al. Reproductive factors and serum uric acid levels in females from the general population: the KORA F4 study. PloS one. 2012;7(3):e32668. doi:10.1371/journal.pone.0032668.</mixed-citation><mixed-citation xml:lang="en">Stöckl D, Döring A, Thorand B, et al. Reproductive factors and serum uric acid levels in females from the general population: the KORA F4 study. PloS one. 2012;7(3):e32668. doi:10.1371/journal.pone.0032668.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">He H, Pan L, Liu F, et al. The mediation effect of body compo sition on the association between menopause and hyperuricemia: evidence from China National Health Survey. Frontiers in Endocrinology. 2022;13:879384. doi:10.3389/fendo.2022.879384.</mixed-citation><mixed-citation xml:lang="en">He H, Pan L, Liu F, et al. The mediation effect of body compo sition on the association between menopause and hyperuricemia: evidence from China National Health Survey. Frontiers in Endocrinology. 2022;13:879384. doi:10.3389/fendo.2022.879384.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Simon JA, Lin F, Vittinghoff E, Bittner V. The relation of postmenopausal hormone therapy to serum uric acid and the risk of coronary heart disease events: the Heart and Estrogen-Progestin Replacement Study (HERS). Annals of epidemiology. 2006;16(2):138-45. doi:10.1016/j.annepidem.2005.04.003.</mixed-citation><mixed-citation xml:lang="en">Simon JA, Lin F, Vittinghoff E, Bittner V. The relation of postmenopausal hormone therapy to serum uric acid and the risk of coronary heart disease events: the Heart and Estrogen-Progestin Replacement Study (HERS). Annals of epidemiology. 2006;16(2):138-45. doi:10.1016/j.annepidem.2005.04.003.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nature Reviews Rheumatology. 2020;16(7):380-90. doi:10.1038/s41584-020-0441-1.</mixed-citation><mixed-citation xml:lang="en">Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nature Reviews Rheumatology. 2020;16(7):380-90. doi:10.1038/s41584-020-0441-1.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Feig DI. The role of uric acid in the pathogenesis of hyper tension in the young. The journal of clinical hypertension. 2012;14(6): 346-52. doi:10.1111/j.1751-7176.2012.00662.x.</mixed-citation><mixed-citation xml:lang="en">Feig DI. The role of uric acid in the pathogenesis of hyper tension in the young. The journal of clinical hypertension. 2012;14(6): 346-52. doi:10.1111/j.1751-7176.2012.00662.x.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Wang J, Qin T, Chen J, et al. Hyperuricemia and risk of inci dent hyper tension: a systematic review and meta-analysis of observational studies. PloS one. 2014;9(12):e114259. doi:10.1371/journal.pone.0114259.</mixed-citation><mixed-citation xml:lang="en">Wang J, Qin T, Chen J, et al. Hyperuricemia and risk of inci dent hyper tension: a systematic review and meta-analysis of observational studies. PloS one. 2014;9(12):e114259. doi:10.1371/journal.pone.0114259.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Qin T, Zhou X, Wang J, et al. Hyperuricemia and the prognosis of hypertensive patients: a systematic review and meta‐analysis. The Journal of Clinical Hypertension. 2016;18(12):1268-78. doi:10.1111/jch.12855.</mixed-citation><mixed-citation xml:lang="en">Qin T, Zhou X, Wang J, et al. Hyperuricemia and the prognosis of hypertensive patients: a systematic review and meta‐analysis. The Journal of Clinical Hypertension. 2016;18(12):1268-78. doi:10.1111/jch.12855.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Gruszka K, Drożdż T, Wojciechowska W, et al. Effects of uric acidlowering therapy in patients with essential arterial hypertension. Blood Pressure Monitoring. 2022;27(3):152-60. doi:10.1097/MBP.0000000000000578.</mixed-citation><mixed-citation xml:lang="en">Gruszka K, Drożdż T, Wojciechowska W, et al. Effects of uric acidlowering therapy in patients with essential arterial hypertension. Blood Pressure Monitoring. 2022;27(3):152-60. doi:10.1097/MBP.0000000000000578.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
